Serrasyn

What is Serrapeptase?

Serrapeptase Serrasyn® The Silkworm Enzyme
 

Serrasyn® is a high quality pharmaceutical grade Serrapeptase formulation which is defined by some as the miracle enzyme, also known as the silkworm enzyme, being actually produced by a friendly bacterium found naturally within the silkworm. The enzyme is utilised by the silkworm to dissolve its protective cocoon without having a detrimental effect on the living cells of the emerging silkmoth. The bacterium responsible for this enzyme is Serratia E15 and the enzyme is also known as Serratia peptidase. The enzyme was discovered in the early 1970’s and is now produced commercially as Serrsyn® through a fermentation process ensuring that the silkworm population is not affected.
 

Serrapeptase References

  • Kee WH. Tan SL, Lee V. Salmon YM. The treatment of breast engorgement with Serrapeptase: a randomised double blind controlled trial. Singapore Med J. 1989:30(1): 48-54.
  • Mizukoshi, D. et al. A double blind clinical study of Serrapeptase in the treatment of chronic sinusitis. Igaku Ayrni 109:50-62.1979.
  • Carratu, L. et al. Physio-chemical and rheological research on mucolytic activity of Serrapeptase in chronic broncho-pneumopathies. Curr. Ther. Res. 28(6): 937-951. 1980.
  • Braga, P.C. et al. Effects of Serrapeptase on muco-ciliary clearance in patients with chronic bronchitis. Curr. Ther. Res. 29(5): 738-744,1981.
  • Mazzonie, A. et al. Evaluation of Serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double blind randomised trial versus placebo. J. Int. Med. Res. 18(5): 379-388,1990.
  • Kakinumu, A. et al. Regression of fibrinolysis in scalded rats by administration of Serrapeptase. Biochem. Pharmacol. 31:2861-2866,1982.
  • Marly, M. Enzymotherapie anti-inflammatoire a l’aide de la Serrapeptase: resultats cliniques en traumatologie et en ORL. C RTherapeut. 3:9-19,1985.
  • Odagiri, J. et al. Clinical applications of Serrapeptase in sinusitis. Med. Consult. New Remedy 6:201-209, 1979.
  • Yamazaki, J. et al. Anti-inflammatory activity of Serrapeptase, a protease produced by a strain of Serratia. Folia Pharmacol. Japon. 6^302-314,1967.
  • Harad, Y. Clinical efficacy of Serrapeptase on buccal swelling after radical operation for chronic sinusitis. Igaku Ayumi 123:768-778.1982.
  • Matsudo, A. et at. Effect of Serrapeptase on inflammatory oedema following operation for thyropid disease. Med. Consult. New Remedy 18:171-175, 1981.
  • Fujitani, T. et al. Effect of anti-inflammatory agent on transfer of antibiotics to the maxillary sinus mucosa in chronic sinusitis. Otorhinolaryngol. Clin. North Am. 66:557-565. 1976.
  • Tago. T. and Mitsui, S. Effects of Serrapeptase in dissolution of sputum, especially in patients with bronchial asthma. Jap. Clin. Exp. Med. 49:222-228, 1972.
  • Mazzonie, A. et al. Evaluation of Serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double blind randomised trial versus placebo. J. int. Med. Res. 18(5): 379-388,1990.
  • Kase, Y. et al. A new method for evaluating mucolytic expectorant activity and its application. II. Application to two proteolytic enzymes, Serrapeptase and seaprose. Arzneimittelforschung 32:374-378,1982.
  • Marriott, C. Modification of the rheoloaical properties of mucus by drugs. Adv. Exp. Med. Biol. 144^75-84, 1982.
  • Majima. Y. et al. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am. Rev. Respit. Dis. 141:79-83.1990.
  • Miyata, K. Intestinal absorption of Serrapeptase. J ApplBiochem. 1980:2:111-16.
  • Aso T. et al. Breast engorgement and its treatment: Clinical effects of (Serrapeptase) an anti-inflammatory enzyme preparation. The world of Obstetrics and Gynaecology (Japanese). 1981:33:371-9.
  • Esch PM, Gemgross H. Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joints in treatment with Serrapeptase a prospective study (German). FortschrMed. 1989; 107(4): 67-8, 71-2.
  • Majima Y, lnagaki M, Hirata K. Takeuchi K, M orishita A, Sakakura Y. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. 1988; 244(6):355-9.
  • Selan L, Berlutti F, Passariello C. Comodi-Ballanti MR, Thaller MC. Proteolytic enzymes: a new treatment strategy for prosthetic infections? Antimicrob Agents Cheroother. 1993; 37(12): 2618-21.
  • Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu H, Hirata M, Arai T, et al. Augmentation by Serrapeptase of tissue permeation by cefotiam (Japanese). Jpn JAntibiot. 1986; 39(3): 761-71.